Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
Hong Kong · Delayed Price · Currency is HKD 2.370
-0.005 (-0.21%)
Oct 30, 2026, 4:08 PM HKT
HKG:1349 Revenue
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical had revenue of 157.48M CNY in the quarter ending September 30, 2026, a decrease of -2.18%. This brings the company's total for the last twelve months to 664.43M, down -6.63% year-over-year. In the year 2025, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical had annual revenue of 685.80M, down -3.33%. That makes Shanghai Fudan-Zhangjiang Bio-Pharmaceutical the 22,723rd largest company in the world by revenue and 1,332nd in Hong Kong.
Revenue (ttm)
664.43M CNY
Revenue Growth
-6.63%
P/S Ratio
8.47
Revenue / Employee
797.64K CNY
Employees
833
Market Cap
6.59B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 685.80M | -23.61M | -3.33% |
| Dec 31, 2024 | 709.40M | -141.33M | -16.61% |
| Dec 31, 2023 | 850.73M | -180.43M | -17.50% |
| Dec 31, 2022 | 1.03B | -109.15M | -9.57% |
| Dec 31, 2021 | 1.14B | 306.51M | 36.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.